TITLE

HIV breakthroughs

AUTHOR(S)
O'Connor, Jeremy
PUB. DATE
August 1996
SOURCE
Financial World;8/12/96, Vol. 165 Issue 11, p16
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the development of an anti-HIV drug known as protease inhibitors. Features of the drug; Impact on the level of HIV virus; Estimated amount of that the market for the drugs will grow within a year; Five companies that markets the drug.
ACCESSION #
9608133562

 

Related Articles

  • Why anti-HIV drug loses effectiveness.  // USA Today Magazine;Oct96, Vol. 125 Issue 2617, p14 

    Reports on an investigation into why the anti-HIV drug saquinavir seems to lose effectiveness over time. Discovery of Jonathan M. Schapiro and associates that some people are not taking the drug as directed; How saquinavir, a protease inhibitor, works; Importance of taking the drug as prescribed.

  • HIV drug scare.  // New Scientist;9/07/96, Vol. 151 Issue 2046, p13 

    Reports on the warnings received by doctors in Europe after the approval of the use of ritonavir, a protease inhibitor, to treat HIV. Drug's ability to cause spontaneous bleeding in hemophiliacs.

  • Ritonavir for advanced HIV infection.  // American Family Physician;7/1/1996, Vol. 54 Issue 1, p372 

    Reports that the United States Food and Drug Administration has approved the protease inhibitor ritonavir for the treatment of patients with human immunodeficiency virus (HIV) infection. Combination of ritonavir with nucleoside analogs or as monotherapy; Clinical trials on the efficacy of...

  • Physicians face new contradictions HIV care. Voelker, Rebecca // JAMA: Journal of the American Medical Association;05/21/97, Vol. 277 Issue 19, p1504 

    Reports that the life-extending properties of protease inhibitors have created a clinical paradox for physicians treating patients infected with the human immunodeficiency virus (HIV). Comments by Lisa Capaldini, MD, at the 9th National AIDS Update Conference;Controversy as to when to start...

  • Compliance and dosage critical in HIV suppression by protease inhibition.  // AIDS Patient Care & STDs;Dec96, Vol. 10 Issue 6, p377 

    Reports that starting and maintaining protease inhibitor therapy at the recommended dosages delays the development of resistant HIV virus and assists in long-term viral suppression. Presentation of indinavir (Crixivan) data.

  • Amprenavir made available through early access program.  // AIDS Patient Care & STDs;Dec98, Vol. 12 Issue 12, p939 

    Announces the availability of the investigational anti-HIV protease inhibitor Agenerase to patients failing protease inhibitor-containing regimens through an early access program. Three options for obtaining the Agenerase drug under the early access program; Requirement for patients to receive...

  • Agenerase shows promise in treatment-naive and treatment-experienced HIV patients.  // AIDS Patient Care & STDs;Feb99, Vol. 13 Issue 2, p128 

    Reports on a small pilot study which evaluated the safety and efficacy of the HIV drug Agenerase in a double protease inhibitor regimen in the absence of NRTI therapy. Presentation of results at the 4th International Congress on Drug Therapy in Infection; Promise of Agenerase in treatment-naive...

  • Editorial Response: Discordance between Virological, Immunologic, and Clinical Outcomes of Therapy with Protease Inhibitors among Human Immunodeficiency Virus-Infected Patients. Goetz, Matthew Bidwell // Clinical Infectious Diseases;12/1/1999, Vol. 29 Issue 6, p1431 

    Comments on the findings of I. Mezzaroma, M. Carlesimo, E. Pinter et al on the occurrence of discordant virological and immunologic responses among HIV-infected patients who had received protease inhibitor-based antiretroviral therapy, published in the December 1999 issue of the journal...

  • HIV Protease Inhibitor--Related Lipodystrophy Syndrome. Carr, Andrew // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS135 

    Explores the association of HIV protease inhibitor (PI) therapy with lipodystrophy syndrome. Occurrence of peripheral lipoatrophy during the course of the therapy; Asymptomatic and nonketotic clinical presentation in diabetes associated with PI therapy; Abnormal lipodystrophy and metabolic...

Share

Other Topics